Get notified when RGNX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsREGENXBIO shareholders reject executive stock option exchange, approve program for staff
Filed June 3, 2026 · Period ending May 29, 2026 · ~1 min read
Key Changes
-
medium
Shareholders voted down a stock option exchange program for executives (21M against vs 14M for), signaling concern about executive compensation practices while approving a similar program for non-executive employees.
Item 5.07: Voting Results verify on EDGAR → -
medium
Company launched stock option exchange for non-executives (June 3-July 1), allowing employees to swap options with exercise prices at or above $18 for fewer new options at current market price, indicating stock has traded below $18.
Item 8.01: Exchange Program verify on EDGAR → -
low
Three Class II directors re-elected to serve until 2029: Jean Bennett, Jerry Karabelas, and Daniel Tassé, all receiving majority shareholder support in routine annual meeting vote.
Item 5.07: Director Elections verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.
Partner
Trade RGNX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify